NCT02162836View on ClinicalTrials.gov

A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 27, 2014

Primary Completion Date

May 27, 2019

Study Completion Date

May 27, 2019

Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
DRUG

JNJ-56021927

Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.

Trial Locations (4)

Unknown

Fukuoka

Gifu

Matsuyama

Yokohama

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY